I've mentioned Chemomab Therapeutics Ltd (NASDAQ:CMMB) for the bulls out there. On Friday, Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $42 per share. It seems that analysts are also seeing what I'm seeing, a stock trading at bargain prices with a tremendous potential going forward and a very low float. From a technical standpoint, the stock has built a good support around $19.2 and $20 recently and does have the chance to go up. Any breakout above the $25 level next week would be a positive sign.